Background: Surgical mortality data are collected routinely in high-income countries, yet virtually no low-or middle-income countries have outcome surveillance in place. The aim was prospectively to collect worldwide mortality data following emergency abdominal surgery, comparing findings across countries with a low, middle or high Human Development Index (HDI).Methods: This was a prospective, multicentre, cohort study. Self-selected hospitals performing emergency surgery submitted prespecified data for consecutive patients from at least one 2-week interval during July to December 2014. Postoperative mortality was analysed by hierarchical multivariable logistic regression.

Acetylsalicylic acid (ASA) in combination with metoclopramide has been frequently used in clinical trials in the acute treatment of migraine attacks. Recently the efficacy of a new high buffered formulation of 1000 mg effervescent ASA without metoclopramide compared to placebo has been shown. To further confirm the efficacy of this new formulation in comparison with a triptan and a nonsteroidal anti-inflammatory drug (ibuprofen) a three-fold crossover, double-blind, randomized trial with 312 patients was conducted in Germany, Italy and Spain. Effervescent ASA (1000 mg) was compared to encapsulated sumatriptan (50 mg), ibuprofen (400 mg) and placebo. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (primary endpoint) was 52.5% for ASA, 60.2% for ibuprofen, 55.8% for sumatriptan and 30.6% for placebo. All active treatments were superior to placebo (P < 0.0001), whereas active treatments were not statistically different. The number of patients who were pain-free at 2 h was 27.1%, 33.2%, 37.1% and 12.6% for those treated with ASA, ibuprofen, sumatriptan or placebo, respectively. The difference between ASA and sumatriptan was statistically significant (P = 0.025). With respect to other secondary efficacy criteria and accompanying symptoms no statistically significant differences between ASA and ibuprofen or sumatriptan were found. Drug-related adverse events were reported in 4.1%, 5.7%, 6.6% and 4.5% of patients treated with ASA, ibuprofen sumatriptan or placebo. This study showed that 1000 mg effervescent ASA is as effective as 50 mg sumatriptan and 400 mg ibuprofen in the treatment of migraine attacks regarding headache relief from moderate/severe to mild/no pain at 2 h. Regarding pain-free at 2 h sumatriptan was most effective.

The use of Atmospheric Pressure Spatial Atomic Layer Deposition (AP-SALD) has gained popularity in the last decade. The success of this technique relies on the possibility to deposit thin films in a fast, vacuum-free, low-cost, low-damage, and high throughput way. In this work, we present ZnO and Aluminium doped ZnO (AZO) films deposited by AP-SALD at low temperature (<220 C) with high uniformity and conformity. The ZnO films present a high transparency of 80%-90% in the visible range, with a tuneable band-gap, between 3.30 eV and 3.55 eV, controlled by the deposition temperature. The carrier density reaches values greater than 3 Â 10 19 cm À3 , while the electron mobility of the films is as high as 5.5 cm 2 V À1 s À1 , resulting in an optimum resistivity of 5 Â 10 À2 X cm. By doping ZnO with aluminium, the resistivity decreases down to 5.57 Â 10 À3 X cm, as a result of a significant increase in the carrier density up to 4.25 Â 10 20 cm À3 . The combination of ZnO thin films with p-type cuprous oxide (Cu 2 O), deposited by aerosol assisted metal organic chemical vapor deposition, allowed the formation of oxidebased pn junctions. The dark I-V characteristic curve confirms a rectifying behaviour, opening the window for the production of all-oxide solar cells completely by chemical vapour deposition methods. We also show the potential of AP-SALD to deposit AZO as a transparent conductive oxide layer for silicon heterojunction solar cells. Published by AIP Publishing. [http://dx.